Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
SLS009 / SELLAS Life Sciences
NCT06375733: A Study of GFH009 in Combination with Zanubrutinib in Subjects with Relapsed or Refractory DLBCL	Recruiting	1/2	51	RoW	GFH009, Zanubrutinib	Genfleet Therapeutics (Shanghai) Inc.	Large B-cell Lymphoma	12/26	12/26
GFH009X2101, NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies	Recruiting	1/2	160	US, RoW	SLS009, GFH009, venetoclax, Venclexta, azacitidine, Vidaza, azacytidine	Sellas Life Sciences Group, Sellas Life Sciences Group	Hematologic Malignancies	06/25	12/25
NCT05934513: A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)	Recruiting	1/2	95	RoW	GFH009	Genfleet Therapeutics (Shanghai) Inc.	Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)	12/25	06/26